ArticleNature cancer2026
A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.
Abstract read
In one paragraph
Article in Nature cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Article
- Spatial transcriptomics identifies a suppressive, T-cell-excluded tumor microenvironment in extramedullary myeloma.Blood advances · 2026Article
- 3D biomimetic microgel platform for multiple myeloma: Approaching tumor microenvironment on cell lines and patient-derived cells.Materials today. Bio · 2026Article
- Diagnosis and management of immune effector cell-associated enterocolitis after ciltacabtagene autoleucel.Blood advances · 2026Article
- Stromal and endothelial transcriptional changes during progression from MGUS to myeloma and after treatment response.Nature communications · 2026Article
- Multiplexed Imaging Reveals Immune-Metabolic Niches in Multiple Myeloma Linked to Progression and Bone Disease.Blood cancer discovery · 2026Article
- Comparative Molecular Insights and Computational Modeling of Multiple Myeloma and Osteosarcoma.International journal of molecular sciences · 2026Review
- Prognostic value of the neutrophil-to-lymphocyte ratio in POEMS syndrome.Clinical and experimental medicine · 2026Article
- Spatial multi-omics of multiple myeloma uncovers niche-dependent pro-myeloma and immunosuppressive signaling in the bone marrow and extramedullary lesions.bioRxiv : the preprint server for biology · 2026Article
- A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.Nature cancer · 2026Article
- Immunophenotypic changes in the tumor and tumor microenvironment during progression to multiple myeloma.PLoS genetics · 2025Article
- Review
- Article
- Cilta-cel salvages ide-cel failure in relapsed multiple myeloma by driving distinct immune responses.medRxiv : the preprint server for health sciences · 2025Article
- Article
- Inhibition of acyl-CoA synthetase long-chain isozymes decreases multiple myeloma cell proliferation and causes mitochondrial dysfunction.Molecular oncology · 2025Article
- Controversies in smoldering multiple myeloma: finding the optimal approach for treatment initiation.The oncologist · 2025Article
Corrections and comments
- Update of
Authors and funding
64 authors.
William C Pilcher *Coultier Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-8544-4967
Lijun Yao *Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Edgar Gonzalez-Kozlova *Tisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0002-6948-0626
Yered Pita-Juarez *Beth Israel Deaconess Medical Center, Boston, MA, USA.
Dimitra Karagkouni *Beth Israel Deaconess Medical Center, Boston, MA, USA.
Chaitanya R Acharya *MMRF, Norwalk, CT, USA.
Marina E MichaudDepartment of Pediatrics, Emory School of Medicine, Atlanta, GA, USA.
Mark HamiltonMMRF, Norwalk, CT, USA.ORCID http://orcid.org/0000-0003-2931-1307
Shivani NandaBeth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6358-2392
Yizhe SongDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0001-8760-6432
Kazuhito SatoDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Julia T WangDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-2233-8841
Sarthak SatpathyDepartment of Biomedical Informatics, Emory School of Medicine, Atlanta, GA, USA.
Yuling MaBeth Israel Deaconess Medical Center, Boston, MA, USA.
Jessica SchulmanMMRF, Norwalk, CT, USA.
Darwin D'SouzaTisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Reyka G JayasingheDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Denis OhlstromCoultier Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-1920-6319
Katherine E FergusonSchool of Biological Sciences, Georgia Institute of Technology, Atlanta, GA, USA.
Giulia CheloniBeth Israel Deaconess Medical Center, Boston, MA, USA.
Mojtaba BakhtiariDepartment of Pediatrics, Emory School of Medicine, Atlanta, GA, USA.
Nick PabustanMMRF, Norwalk, CT, USA.
Kai NieTisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Jennifer A FoltzDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Isabella SaldarriagaBeth Israel Deaconess Medical Center, Boston, MA, USA.
Rania AlaaeldinDepartment of Pediatrics, Emory School of Medicine, Atlanta, GA, USA.
Eva LepistoMMRF, Norwalk, CT, USA.
Rachel ChenTisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Mark A FialaBone Marrow Transplantation & Leukemia Section, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-0208-5023
Beena E ThomasDepartment of Pediatrics, Emory School of Medicine, Atlanta, GA, USA.
April CookMMRF, Norwalk, CT, USA.
Junia Vieira Dos SantosTisch Cancer Institute, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Chiang I-LingDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.
Igor FigueiredoTisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Julie FortierBone Marrow Transplantation & Leukemia Section, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
Michael SladeBone Marrow Transplantation & Leukemia Section, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0001-8092-6644
Stephen T OhDivision of Hematology, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Michael P RettigDivision of Oncology, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-1091-0564
Emilie AndersonMayo Clinic, Rochester, MN, USA.
Ying LiMayo Clinic, Rochester, MN, USA.
Surendra DasariMayo Clinic, Rochester, MN, USA.
Michael A StrausbauchMayo Clinic, Rochester, MN, USA.
Vernadette A SimonMayo Clinic, Rochester, MN, USA.
Immune Atlas Consortium
Emir RadkevichTisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Adeeb H RahmanTisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Zhihong ChenTisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0001-7403-7015
Alessandro LaganaTisch Cancer Institute, Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
John F DiPersioDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA.ORCID http://orcid.org/0000-0002-0429-3133
Jacalyn RosenblattBeth Israel Deaconess Medical Center, Boston, MA, USA.
Seunghee Kim-SchulzeTisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.ORCID http://orcid.org/0000-0003-0192-4400
Sagar LonialDepartment of Pediatrics, Emory School of Medicine, Atlanta, GA, USA.
Shaji KumarDivision of Oncology, Washington University School of Medicine, St. Louis, MO, USA.ORCID http://orcid.org/0000-0001-5392-9284
Swati S BhasinDepartment of Pediatrics, Emory School of Medicine, Atlanta, GA, USA.
Taxiarchis KourelisMayo Clinic, Rochester, MN, USA.
Madhav V DhodapkarDepartment of Hematology Oncology, Emory School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-8249-5988
Ravi VijBone Marrow Transplantation & Leukemia Section, Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA.
David AviganBeth Israel Deaconess Medical Center, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4624-6017
Hearn J ChoTisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
George MulliganMMRF, Norwalk, CT, USA. mulligang@themmrf.org.ORCID http://orcid.org/0009-0009-5084-9604
Li DingDepartment of Medicine, Washington University in St. Louis, St. Louis, MO, USA. lding@genome.wustl.edu.ORCID http://orcid.org/0000-0003-1517-2975
Sacha GnjaticTisch Cancer Institute, Department of Immunology and Immunotherapy, Icahn School of Medicine at Mount Sinai, New York, NY, USA. sacha.gnjatic@mssm.edu.ORCID http://orcid.org/0000-0001-5643-9520
Ioannis S VlachosBeth Israel Deaconess Medical Center, Boston, MA, USA. ivlachos@bidmc.harvard.edu.ORCID http://orcid.org/0000-0002-8849-808X
Manoj BhasinCoultier Department of Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, USA. manoj.bhasin@emory.edu.ORCID http://orcid.org/0000-0001-5172-420X
Funding
Conduits: Mount Sinai Health System Translational Science HubUL1TR004419 · NCATS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Rosalind J Wright · 2022 to 2026
$46.4MTHE TISCH CANCER INSTITUTE - CANCER CENTER SUPPORT GRANTP30CA196521 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Ramon E Parsons · 2015 to 2026
$35.4MHigh-Dimensional Immune Monitoring of NCI-Supported Immunotherapy TrialsU24CA224319 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI Sacha Gnjatic, Seunghee Kim-Schulze · 2017 to 2026
$21.5MPaul Calabresi Program in Clinical/Translational Research at Mayo ClinicK12CA090628 · NCI · MAYO CLINIC ROCHESTER · PI WEROHA, SARAVUT · 2001 to 2025
$19.7MWASHINGTON UNIVERSITY HUMAN TUMOR ATLAS RESEARCH CENTERU2CCA233303 · NCI · WASHINGTON UNIVERSITY · PI DING, LI · 2018 to 2023
$9.7MOptimizing Hematopoietic Stem Cell Transplantation For The Treatment Of Hematological MalignanciesR35CA210084 · NCI · WASHINGTON UNIVERSITY · PI John F. Dipersio · 2017 to 2026
$7.8MPan-Cancer characterization of 3’UTR somatic mutations controlling tumor immune evasionR01CA258776 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Ioannis Vlachos · 2022 to 2026
$2.9MCharacterizing and predicting colitis in immune checkpoint blockade-treated cancer patientsU01DK124165 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI COLOMBEL, JEAN-FREDERIC, FAITH, JEREMIAH JAMES · 2020 to 2024
$2.9MBM NICHE DISRUPTION AND IMMUNOTHERAPY IN HEMATOLOGICAL MALIGNANCIESR50CA211466 · NCI · WASHINGTON UNIVERSITY · PI Michael Rettig · 2016 to 2026
$2.3MDeep Discovery and Clinical Interpretation of Germline and Somatic Cancer DriversU24CA211006 · NCI · WASHINGTON UNIVERSITY · PI DING, LI, GOVINDAN, RAMASWAMY · 2016 to 2020
$1.8MNCATS NIH HHS UL1 TR004419NCI NIH HHS K12 CA090628NCI NIH HHS P30 CA196521NCI NIH HHS R01 CA258776NCI NIH HHS R35 CA210084NCI NIH HHS R50 CA211466NCI NIH HHS U24 CA211006NCI NIH HHS U24 CA224319NCI NIH HHS U2C CA233303NIDDK NIH HHS U01 DK124165U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) 5K12CA090628U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) P30CA196521U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) PJ000021702U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R01CA258776U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R50CA211466U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U01DK124165U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U24CA211006U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U24CA224319U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) U2CCA233303
Abstract
Multiple myeloma (MM) remains incurable despite advances in treatment options. Although tumor subtypes and specific DNA abnormalities are linked to worse prognosis, the impact of immune dysfunction on disease emergence and/or treatment sensitivity remains unclear. We developed an Immune Atlas of MM by generating profiles of 1,397,272 single cells from the bone marrow (BM) of 337 newly diagnosed participants and characterized immune and hematopoietic cell populations. Cytogenetic risk-based analysis revealed heterogeneous associations with T cells of BM, with 17p13 deletion showing distinct enrichment of a type 1 interferon signature. The disease progression-based analysis revealed the presence of a proinflammatory immune senescence-associated secretory phenotype in rapidly progressing participants. Furthermore, signaling analyses suggested active intercellular communication involving a proliferation-inducing ligand and B cell maturation antigen, potentially promoting tumor growth and survival. Lastly, using independent discovery and validation cohorts, we demonstrated that integrating immune cell signatures with known tumor cytogenetics and individual characteristics significantly improves stratification for the prediction of survival.
Indexed as
Bone MarrowMultiple MyelomaSingle-Cell AnalysisTumor MicroenvironmentDisease ProgressionFemaleHumansMalePrognosis
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.